Fresenius Kabi Acquires Ivenix For $240M To Expand Presence In Infusion Pump Market

Fresenius Kabi will pay up to $240m for Massachusetts-based Invenix to expand its infusion pump portfolio. Simultaneously, the company also made a major move to bolster its biosimilars business by acquiring a majority stake in mAbxience.